Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatOtherSprague-Dawleyn = n = 4 per group for extracellular matrix or saline in each…Intratracheal instillation via a 14-gauge tracheal cannula, or nebulisation through the tracheal cannula using a vibrating mesh nebuliser generating 4 to 6 micrometre droplets3.2 mg/mL preparation, 1.5 mg delivered per animal; in vitr…Single dose given before injury, immediately before recovery from anaesthesia a…
Model: Hyperoxia-induced acute lung injury, with anaesthetised intubated rats exposed either to continuous 90% oxygen for 3 days or to intermittent 90% oxygen for 24 h alternating with 21% oxygen for 24 h over three cycles across 6 days; parallel in vitro model of human A549 lung epithelial cells exposed to 95% oxygen for 24 h
Compared with saline, extracellular matrix treatment significantly reduced hyperoxia-induced alveolar septal thickening, oedema and exudation, and lowered caspase-8 activity by 14 to 18% during both continuous and intermittent hyperoxia and protein carbonyl by about 8% in both. Oxidative DNA damage…
Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.